sPLA2-IIF deficiency in keratinocytes alleviates psoriasis and skin cancer, accompanied by reduction of skin P-LPE level (47), suggesting that the sPLA2-IIF–EV–P-LPE axis is a novel drug target for epidermal-hyperplasic diseases. This evidence concerns the gene PLA2G2F and skin cancer.